UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2026

 

Commission File Number: 001-43342

 

 

Veraxa Biotech AG

 

 

Talacker 35

8001 Zurich, Switzerland

 

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒          Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

Extraordinary General Meeting of Shareholders

 

On July 2, 2026, Veraxa Biotech AG (the “Company”) issued a notice for an Extraordinary General Meeting of Shareholders to be held on July 24, 2026 (the “Meeting”). The Company has fixed July 20, 2026 as the record date for determination of persons entitled to receive notice of the Meeting.

 

A copy of the notice is attached as Exhibit 99.1 to this report on Form 6-K and is incorporated by reference herein.

 

Cell Line Development for BiTAC-TCE Technology Platform

 

On July 2, 2026, the Company issued a press release announcing the initiation of cell line development for its lead BiTAC T-cell engager (“BiTAC-TCE”) program.

 

A copy of the press release is attached as Exhibit 99.2 to this report on Form 6-K and is incorporated by reference herein.

 

Business Update and Further Details on Partnering Strategy and Development Timelines

 

On July 6, 2026, the Company issued a press release announcing details of its partnering strategy and development timelines.

 

A copy of the press release is attached as Exhibit 99.3 to this report on Form 6-K and is incorporated by reference herein.

 

EXHIBIT INDEX

 

Exhibit		Description of Exhibit
99.1		Notice of Meeting
99.2		Press Release dated July 2, 2026
99.3		Press Release dated July 6, 2026

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	VERAXA BIOTECH AG
Date: July 6, 2026	By:	/s/ Christoph Antz
	Name:	Christoph Antz
	Title:	Chief Executive Officer

 

	By:	/s/ Oliver Baumann
	Name:	Oliver Baumann
	Title:	Chairman of the Board of Directors

 

 

Exhibit 99.1

 

 

Anzahl Aktien / Total shares:

 

		A-PRIORITY      Post CH AG Veraxa Biotech AG, Talacker 35
P.P.	CH-8001
	Zürich

 

 

 

 

 

Anmeldung / Registration

 

für die ausserordentliche Generalversammlung der Veraxa Biotech AG vom 24. Juli 2026

for the extraordinary general meeting of shareholders on Friday, 24 July

 

☐

Ich nehme an der ausserordentlichen Generalversammlung persönlich teil und weise mich für die Zutrittskontrolle mit einem amtlichen Ausweis (Identitätskarte, Reisepass oder Führerschein) aus.

I will attend the extraordinary general meeting in person and identify myself at the admission control with an official ID document: identity card, passport, or driver’s license

 

Ich erteile Vollmacht für meine Stimme an:

I grant power of attorney for my vote to:

 

☐

die unabhängige Stimmrechtsvertreterin, Maya McNally, McNally GmbH, Rechtsanwälte, Gartenstrasse 25, Postfach, 8027 Zürich, Schweiz

the independent voting rights representative, Maya McNally, McNally GmbH, Attorneys-at-Law, Gartenstrasse 25, P.O. Box, 8027 Zurich, Switzerland

 

Wenn Sie keine Weisungen zu den in der Einladung bekannt gegebenen Anträgen und/oder keine allgemeine Weisung erteilen, wird die unabhängige Stimmrechtsvertreterin sich enthalten.

If you do not issue any instructions regarding the proposals announced in the invitation and/or do not issue any general instruction, the independent voting rights representative will abstain.

 

Die Vollmachtserteilung und Weisungen an die unabhängige Stimmrechtsvertreterin können auch elektronisch über die Aktionärsplattform Aequitec erteilt werden. Melden Sie sich mit den Login-Informationen an. Nach der Anmeldung finden Sie alle Anträge und Begleitinformationen zur Generalversammlung unter dem Menüpunkt “Meetings”.

The granting of power of attorney and instructions to the independent voting rights representative may also be submitted electronically via the Aequitec shareholder platform. Log in using your login details. After logging in, you will find all proposals and accompanying information regarding the General Meeting under the menu item “Meetings”.

 

 

Elektronische Vollmachtserteilung & Weisung via Aktionärsplattform Aequitec:
Electronic granting of power of attorney and instructions via the Aequitec shareholder platform:
Website:	app.aequitec.ch
Login:
Password:

 

☐

folgende Person, die sich für die Zutrittskontrolle mit einem amtlichen Ausweis (Identitätskarte, Reisepass oder Führerschein) ausweist.

the following person, who will identify themselves at the admission control with an official ID document: identity card, passport, or driver’s license.

 

Name und Vorname:
Last name, first name

 

E-Mail-Adresse der bevollmächtigten Person:
Email address of the authorized person

 

Datum / Date:

Unterschrift / Signature:

 

STIMMRECHTSWEISUNGSFORMULAR / VOTING INSTRUCTION FORM

 

Einzelweisungen zu in der Einladung bekannt gegebenen Anträgen des Verwaltungs-rates zu den Verhandlungsgegenständen (Traktanden) an den unabhängigen Stimmrechtsvertreter

Individual instructions to the independent voting rights representative regarding the Board of Directors’ proposals on the agenda items announced in the invitation

 

Traktanden				Ja		Nein		Enthaltung
Agenda				Yes		No		Abstention
1		Erhöhung bedingtes Kapital für Aktionärsoptionen 1 und Änderung von Art. 3a der Statuten Increase in Conditional Capital for Shareholder Options 1 and Amendment of Article 3a of the Articles of Association		☐		☐		☐
2		Erhöhung Kapitalband und Änderung von Art. 3d der Statuten Increase Capital Band and Amendment of Article 3d of the Articles of Association		☐		☐		☐
3		Erhöhung Anzahl Mitglieder des Verwaltungsrates und Änderung von Art. 15 der Statuten Increase of Number of Members of the Board of Directors and Amendment of Article 15 of the Articles of Association		☐		☐		☐

 

 

B)	Allgemeine Weisung
B)	General Directive

 

Für den Fall, dass an der Generalversammlung über in der Einladung nicht angekündigte Anträge und/oder über neue Verhandlungsgegenstände abgestimmt wird, beauftrage und ermächtige ich den unabhängigen Stimmrechtsvertreter, sich wie folgt zu verhalten:

In the event that a resolution is put to a vote at the shareholders’ meeting regarding motions not announced in the notice of meeting and/or new items on the agenda, I hereby instruct and authorize the independent proxy to act as follows:

 

	☐	Im Sinne des Antrags des Verwaltungsrates
		In accordance with the motion of the Board of Directors
	☐	Gegen nicht angekündigte Anträge und Anträge zu neuen Verhandlungsgegenständen
		Against unannounced motions and motions regarding new agenda items
	☐	Stimmenthaltung
		Abstention

 

 

 

à	Bitte retournieren Sie für die briefliche Abstimmung Seiten 1-3 mit dem beigelegten Rücksendecouvert.

à	For postal voting, please return pages 1-3 using the enclosed return envelope.

 

 

Zürich, den 2. Juli 2026

 

Veraxa Biotech AG, Zürich

 

Einladung zur ausserordentlichen Generalversammlung der Aktionäre am Freitag, den 24. Juli 2026

Invitation to the Extraordinary General Meeting of Shareholders on Friday, 24 July 2026

 

Sehr geehrte Aktionärinnen und Aktionäre,

Dear Shareholders,

 

Wir freuen uns, Sie zur ausserordentlichen Generalversammlung der Aktionärinnen und Aktionäre der Veraxa Biotech AG einzuladen.

We are pleased to invite you to the Extraordinary General Meeting of Shareholders of Veraxa Biotech AG.

 

Datum:	24. Juli 2026
Date:	24 July 2026
Uhrzeit:	10:00 Uhr (Einlass ab 09:30 Uhr)
Time	10:00 AM (doors open at 09:30 AM)
Ort / Place:	Walder Wyss AG, Seefeldstrasse 123, 8008 Zürich, Switzerland

 

TRAKTANDEN

AGENDA

 

1.

Erhöhung bedingtes Kapital für Aktionärsoptionen 1 und Änderung von Art. 3a der Statuten

Increase in Conditional Capital for Shareholder Options 1 and Amendment of Article 3a of the Articles of Association

 

2.

Erhöhung Kapitalband und Änderung von Art. 3d der Statuten

Increase Capital Band and Amendment of Article 3d of the Articles of Association

 

3.

Erhöhung Anzahl Mitglieder des Verwaltungsrates und Änderung von Art. 15 der Statuten

Increase of Number of Members of the Board of Directors and Amendment of Article 15 of the Articles of Association

 

Text der beantragten Statutenänderungen siehe im Anhang

See Appendix for the text of the proposed amendments to the articles of association.

 

 

Als Aktionärinnen und Aktionäre werden diejenigen Personen anerkannt, welche per 20. Juli 2026 im elektronischen Aktienbuch der Veraxa Biotech AG eingetragen sind. Die gegenseitige Vertretung von Aktionären ist statthaft. Ein zur Vertretung berufener Aktionär hat eine rechtsgültige Vollmacht seitens des vertretenen Aktionärs mitzubringen. Ein entsprechendes Formular haben wir Ihnen zu dieser Einladung beigelegt. Alternativ können Sie auf der Aktionärsplattform www.aequitec.ch einen unabhängigen Stimmrechtsvertreter mandatieren.

Shareholders are defined as those individuals who are registered in the electronic share register of Veraxa Biotech AG as of 20 July 2026. Shareholders may appoint proxies to represent them. A shareholder appointed as a proxy must present a legally valid power of attorney from the shareholder they are representing. We have enclosed the appropriate form with this invitation. Alternatively, you can appoint an independent proxy on the shareholder platform www.aequitec.ch.

 

Wir freuen uns, Sie am 24. Juli 2026 in Zürich begrüssen zu dürfen.

We look forward to welcoming you in Zurich on 24 July 2026.

 

Freundliche Grüsse

Kind regards

 

/s/ Oliver R. Baumann
Oliver R. Baumann
Präsident des Verwaltungsrates
Chairman of the Board of Directors

 

 

Anhang zur Einladung zur ausserordentlichen Generalversammlung der Aktionäre

Appendix to Invitation to the Extraordinary General Meeting of Shareholders’

 

“Artikel 3a – Bedingtes Aktienkapital für Aktionärsoptionen 1		Article 3a – Conditional Capital for Shareholders’ Options 1
Das Aktienkapital der Gesellschaft wird im Maximalbetrag von CHF 459’789 + 25/453 erhöht durch Ausgabe von höchstens 52’071’110 vollständig zu liberierenden Namenaktien mit einem Nennwert von je CHF 100/11’325 durch Ausübung von Rechten oder Anwartschaften auf Erwerb von Aktien (Erwerbsrechte), welche: (a) in Verbindung mit Anleihens- oder ähnlichen Instrumenten, einschliesslich Wandel- oder Optionsanleihen, Darlehen oder anderer Finanzierungsinstrumente, der Gesellschaft oder von Konzerngesellschaften (zusammen nachfolgend “aktiengebundene Finanzierungsinstrumente” genannt) eingeräumt oder auferlegt werden; oder (b) an beliebige Personen (seien es Aktionäre oder Dritte) eingeräumt werden (nachfolgend “Warrants” genannt).		The share capital of the Company may be increased by up to CHF 459,789 + 25/453 by the issue of up to 52,071,110 fullypaid- up registered shares with a par value of CHF 100/11’325 each by exercising rights or entitlements to acquire shares (acquisition rights), which are: (a) granted or imposed in connection with bonds or similar instruments, including convertible bonds or bonds with warrants, loans or other financing instruments, of the Company or of consolidated subsidiaries (hereinafter collectively the “Equity-Linked Financing Instruments”), or (b) granted to any persons (whether shareholders or third parties) (hereinafter referred to as “Warrants”).
Das Bezugsrecht der Aktionäre ist ausgeschlossen.		Existing shareholders’ subscription rights are excluded.
Der Verwaltungsrat ist ermächtigt, bei der Ausgabe von aktiengebundenen Finanzierungsinstrumenten und bei Warrants das Vorwegzeichnungsrecht der Aktionäre zu beschränken oder aufzuheben im Zusammenhang mit (a) der Finanzierung (einschliesslich Refinanzierung) des Erwerbs von Unternehmen, Unternehmensteilen, Beteiligungen oder von neuen Investitionsvorhaben der Gesellschaft oder (b) der Emission auf nationalen oder internationalen Kapitalmärkten oder der Ausgabe an einen oder mehrere strategische Investoren oder Finanzinvestoren.		The Board of Directors is authorized, when issuing Equity- Linked Financing Instruments and Warrants to restrict or cancel shareholders’ advance subscription rights in connection with (a) the financing (including refinancing) of the acquisition of companies, parts of companies, participations or new investment projects of the Company, or (b) the issue on national or international capital markets or to one or more strategic or financial investors.
Soweit das Vorwegzeichnungsrecht ausgeschlossen ist, sind (i) die aktiengebundenen Finanzierungsinstrumente zu Marktbedingungen zu platzieren, (ii) die Ausübungsfrist der Wandelrechte auf höchstens zwanzig Jahre und jene der Optionsrechte auf höchstens zehn Jahre ab dem Zeitpunkt der Emission (oder einer Neufestsetzung der Bedingungen) anzusetzen und (iii) der Wandel- oder Ausübungspreis oder die Berechnungsmethode eines solchen Preises für die neuen Aktien entsprechend Marktbedingungen und -praxis im Zeitpunkt der Emission der aktiengebundenen Finanzierungsinstrumente, der Neufestsetzung der Bedingungen oder der Ausgabe von neuen Aktien festzulegen.		Insofar as the right of advance subscription is excluded, the following conditions shall apply: (i) the Equity-Linked Financing Instruments are to be placed at market conditions; (ii) the exercise period of the conversion rights is to be set at a maximum of 20 years and that of the option rights at a maximum of 10 years from the date of the issue (or of a re-setting of the terms and conditions); and (iii) the conversion or exercise price or the calculation methodology for such price for the new shares is to be set in line with market conditions and practice prevailing at the time of the issue of the Equity-Linked Financing Instruments, of a resetting of the terms and conditions, or of the new shares.
Die Erwerbsrechte sind mittels schriftlicher Mitteilung an die Gesellschaft oder in einer anderen vom Verwaltungsrat festgelegten Form auszuüben.		Acquisition Rights shall be exercised by way of written notice to the company or in another form as determined by the board of directors.”
“Artikel 3d – Kapitalband		Article 3d – Capital Band
Der Verwaltungsrat ist ermächtigt, jederzeit bis zum 31. Dezember 2030 das derzeitige Aktienkapital der Gesellschaft durch die Ausgabe von maximal 70’703’906 Namenaktien mit einem Nennwert von je CHF 100/11’325 um nominal maximal CHF 624’317 + 25/453 zu erhöhen, wobei die obere Grenze des Kapitalbands nominal CHF 1’872’951 + 73/453 und die untere Grenze nominal CHF 1’248’634 + 50/453 beträgt. Mehrfache Erhöhungen (auch in Teilbeträgen) im Rahmen des Kapitalbands, der Befristung und der nachfolgenden Bestimmungen sind zulässig.		The Board of Directors is authorised to increase the current share capital of the Company at any time until 31 December 2030 by a maximum nominal amount of CHF 624,317 + 25/453 by issuing a maximum of 70,703,906 registered shares with a par value of CHF 100/11,325 each (common shares), whereby the upper limit of the capital band is nominally CHF 1’872’951 + 73/453 and the lower limit is nominally CHF 1,248,634 + 50/453. Multiple increases (also in instalments) within the framework of the capital band, the time limit and the following provisions are permitted.

 

 

Der Verwaltungsrat legt den Ausgabebetrag, die Art der Einlagen, den Zeitpunkt der Ausgabe, die Bedingungen der Bezugsrechtsausübung und den Beginn der Dividendenberechtigung fest. Dabei kann der Verwaltungsrat neue Aktien mittels Festübernahme durch eine Bank oder einen anderen Dritten und anschliessenden Angebots an die bisherigen Aktionäre ausgeben. Der Verwaltungsrat ist ermächtigt, den Handel mit Bezugsrechten zu beschränken oder auszuschliessen. Nicht ausgeübte Bezugsrechte kann der Verwaltungsrat verfallen lassen oder diese bzw. die Aktien, für welche Bezugsrechte eingeräumt, aber nicht ausgeübt werden, zu Marktkonditionen platzieren oder anderweitig im Interesse der Gesellschaft verwenden.		The Board of Directors shall determine the amount of share capital to be issued, the type of contribution, the date of issue, the conditions governing the exercise of subscription rights and the commencement of dividend entitlement. The Board of Directors may issue new shares which are underwritten by a bank or other third party and subsequently offered to existing shareholders. The Board of Directors is authorised to restrict or to prohibit trading in the subscription rights to the new shares. In the event of subscription rights not being exercised, the Board of Directors may, at its discretion, either allow such rights to expire worthless, or place them or the shares to which they entitle their holders either at market prices or in some other manner commensurate with the interests of the Company.
Der Verwaltungsrat ist ermächtigt, die Be-zugsrechte der Aktionäre zu entziehen oder zu beschränken und Bezugsrechte einzelnen Aktionären oder Dritten zuzuweisen:		The Board of Directors is authorized to withdraw or limit the subscription rights of shareholders and to allocate subscription rights to individual shareholders or third parties:
(i) sofern die Aktien für die Übernahme von Unternehmen, Unternehmensteilen oder Beteiligungen oder für die Finanzierung oder Refinanzierung solcher Transaktionen, die Umwandlung von Darlehen oder Wertschriften in Aktien, die Finanzierung von neuen Investitionsvorhaben der Gesellschaft, den Erwerb oder die Finanzierung von Produkten, geistigem Eigentum oder Lizenzen oder die Finanzierung von strategischen Initiativen verwendet werden;		(i) of the new shares being used to acquire companies, parts thereof or participations, or for the financing or refinancing of such transactions, for the conversion of loans or securities into shares, for the financing of new investment projects undertaken, the acquisition or financing of products, intellectual property or licenses, or the financing of strategic initiatives undertaken by the Company;
(ii) sofern die Aktien zum Zwecke der Erweiterung des Aktionärskreises im Zusammenhang mit der Kotierung der Aktien an einer Börse, um den Streubesitz zu erhöhen, oder zur Beteiligung von strategischen Partnern verwendet werden;		(ii) of the new shares being used either to extend the shareholder base [in conjunction with the listing of the shares on any stock exchange] to increase the free float or for investment by strategic partners;
(iii) im Fall nationaler oder internationaler (auch privater) Platzierung von Aktien zu Marktkonditionen; oder		(iii) of the new shares being placed nationally or internationally (including by way of private placement) at market conditions;
(iv) sofern die Aktien zum Zwecke einer raschen und flexiblen Beschaffung von Eigenkapital, welche ohne Beschränkung oder Ausschluss des Bezugsrechts nur schwer oder zu schlechteren Bedingungen möglich wäre.		(iv) the new shares being issued for the for the purpose of raising equity capital in a swift and flexible manner, where such raising of capital would be difficult or would only be possible at less favorable conditions if the subscription rights to the new shares were not restricted or withdrawn.”
Art. 15 Abs. 1:		Art. 15 para. 1:
“Der Verwaltungsrat besteht aus bis zu sieben Mitgliedern.		The Board of Directors shall consist of up to seven members.”

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NOTE: All English text is provided solely as a translation of the German original. In case of doubt, the German version shall prevail.

 

 

 

 

 

 

 

Rubrik: Mitteilungen an Gesellschafter

Unterrubrik: Einladung zur Generalversammlung

Publikationsdatum: SHAB 02.07.2026

Öffentlich einsehbar bis: 02.07.2027

Meldungsnummer: UP04-0000008135

 

Publizierende Stelle

 

 

Veraxa Biotech AG, Talacker 35, 8001 Zürich

 

Einladung zur ausserordentlichen

Generalversammlung Veraxa Biotech AG

 

Betroffene Organisation:

Veraxa Biotech AG

CHE-441.201.868

Talacker 35

8001 Zürich

 

Angaben zur Generalversammlung:

24.07.2026, 10:00 Uhr, Walder Wyss AG, Seefeldstrasse 123, 8008 Zürich

 

Einladungstext/Traktanden:

Veraxa Biotech AG, Zürich

 

Einladung zur ausserordentlichen Generalversammlung der Aktionäre am Freitag, den 24. Juli 2026

Invitation to the Extraordinary General Meeting of Shareholders on Friday, 24 July 2026

 

Sehr geehrte Aktionärinnen und Aktionäre,

Dear Shareholders,

 

Wir freuen uns, Sie zur ausserordentlichen Generalversammlung der Aktionärinnen und Aktionäre der Veraxa Biotech AG einzuladen.

We are pleased to invite you to the Extraordinary General Meeting of Shareholders of Veraxa Biotech AG.

 

Datum: 24. Juli 2026

Date: 24 July 2026

 

 

Uhrzeit: 10:00 Uhr (Einlass ab 09:30 Uhr)

Time 10:00 AM (doors open at 09:30 AM)

 

Ort / Place: Walder Wyss AG, Seefeldstrasse 123, 8008 Zürich

 

TRAKTANDEN

AGENDA

 

1. Erhöhung bedingtes Kapital für Aktionärsoptionen 1 und Änderung von Art. 3a der Statuten

Increase in Conditional Capital for Shareholder Options 1 and Amendment of Article 3a of the Articles of Association

 

2. Erhöhung Kapitalband und Änderung von Art. 3d der Statuten

Increase Capital Band and Amendment of Article 3d of the Articles of Association

 

3. Erhöhung Anzahl Mitglieder des Verwaltungsrates und Änderung von Art. 15 der Statuten

Increase of Number of Members of the Board of Directors and Amendment of Article 15 of the Articles of Association

 

Text der beantragten Statutenänderungen siehe im Anhang

See Appendix for the text of the proposed amendments to the articles of association.

 

Als Aktionärinnen und Aktionäre werden diejenigen Personen anerkannt, welche per 20. Juli 2026 im elektronischen Aktienbuch der Veraxa Biotech AG eingetragen sind. Die gegenseitige Vertretung von Aktionären ist statthaft. Ein zur Vertretung berufener Aktionär hat eine rechtsgültige Vollmacht seitens des vertretenen Aktionärs mitzubringen. Alternativ können Sie auf der Aktionärsplattform www.aequitec.ch einen unabhängigen Stimmrechtsvertreter mandatieren.

Shareholders are defined as those individuals who are registered in the electronic share register of Veraxa Biotech AG as of 20 July 2026. Shareholders may appoint proxies to represent them. A shareholder appointed as a proxy must present a legally valid power of attorney from the shareholder they are representing. Alternatively, you can appoint an independent proxy on the shareholder platform www.aequitec.ch.

 

Wir freuen uns, Sie am 24. Juli 2026 in Zürich begrüssen zu dürfen.

We look forward to welcoming you in Zurich on 24 July 2026.

 

Freundliche Grüsse

Kind regards

 

Oliver R. Baumann

 

Präsident des Verwaltungsrates

Chairman of the Board of Directors

 

Anhang zur Einladung zur ausserordentlichen Generalversammlung der Aktionäre

Appendix to Invitation to the Extraordinary General Meeting of Shareholders’

 

Artikel 3a – Bedingtes Aktienkapital für Aktionärsoptionen 1

 

Das Aktienkapital der Gesellschaft wird im Maximalbetrag von CHF 459’789 + 25/453 erhöht durch Ausgabe von höchstens 52’071’110 vollständig zu liberierenden Namenaktien mit einem Nennwert von je CHF 100/11’325 durch Ausübung von Rechten oder Anwartschaften auf Erwerb von Aktien (Erwerbsrechte), welche: (a) in Verbindung mit Anleihens- oder ähnlichen Instrumenten, einschliesslich Wandel- oder Optionsanleihen, Darlehen oder anderer Finanzierungsinstrumente, der Gesellschaft oder von Konzerngesellschaften (zusammen nachfolgend “aktiengebundene Finanzierungsinstrumente” genannt) eingeräumt oder auferlegt werden; oder (b) an beliebige Personen (seien es Aktionäre oder Dritte) eingeräumt werden (nachfolgend “Warrants” genannt).

 

Das Bezugsrecht der Aktionäre ist ausgeschlossen.

 

 

Der Verwaltungsrat ist ermächtigt, bei der Ausgabe von aktiengebundenen Finanzierungsinstrumenten und bei Warrants das Vorwegzeichnungsrecht der Aktionäre zu beschränken oder aufzuheben im Zusammenhang mit (a) der Finanzierung (einschliesslich Refinanzierung) des Erwerbs von Unternehmen, Unternehmensteilen, Beteiligungen oder von neuen Investitionsvorhaben der Gesellschaft oder (b) der Emission auf nationalen oder internationalen Kapitalmärkten oder der Ausgabe an einen oder mehrere strategische Investoren oder Finanzinvestoren.

 

Soweit das Vorwegzeichnungsrecht ausgeschlossen ist, sind (i) die aktiengebundenen Finanzierungsinstrumente zu Marktbedingungen zu platzieren, (ii) die Ausübungsfrist der Wandelrechte auf höchstens zwanzig Jahre und jene der Optionsrechte auf höchstens zehn Jahre ab dem Zeitpunkt der Emission (oder einer Neufestsetzung der Bedingungen) anzusetzen und (iii) der Wandel- oder Ausübungspreis oder die Berechnungsmethode eines solchen Preises für die neuen Aktien entsprechend Marktbedingungen und -praxis im Zeitpunkt der Emission der aktiengebundenen Finanzierungsinstrumente, der Neufestsetzung der Bedingungen oder der Ausgabe von neuen Aktien festzulegen.

 

Die Erwerbsrechte sind mittels schriftlicher Mitteilung an die Gesellschaft oder in einer anderen vom Verwaltungsrat festgelegten Form auszuüben.

 

Article 3a – Conditional Capital for Shareholders’ Options 1

 

The share capital of the Company may be increased by up to CHF 459,789 + 25/453 by the issue of up to 52,071,110 fully-paid-up registered shares with a par value of CHF 100/11’325 each by exercising rights or entitlements to acquire shares (acquisition rights), which are: (a) granted or imposed in connection with bonds or similar instruments, including convertible bonds or bonds with warrants, loans or other financing instruments, of the Company or of consolidated subsidiaries (hereinafter collectively the “Equity-Linked Financing Instruments”), or (b) granted to any persons (whether shareholders or third parties) (hereinafter referred to as “Warrants”).

 

Existing shareholders’ subscription rights are excluded.

 

The Board of Directors is authorized, when issuing Equity-Linked Financing Instruments and Warrants to restrict or cancel shareholders’ advance subscription rights in connection with (a) the financing (including refinancing) of the acquisition of companies, parts of companies, participations or new investment projects of the Company, or (b) the issue on national or international capital markets or to one or more strategic or financial investors.

 

Insofar as the right of advance subscription is excluded, the following conditions shall apply: (i) the Equity-Linked Financing Instruments are to be placed at market conditions; (ii) the exercise period of the conversion rights is to be set at a maximum of 20 years and that of the option rights at a maximum of 10 years from the date of the issue (or of a re-setting of the terms and conditions); and (iii) the conversion or exercise price or the calculation methodology for such price for the new shares is to be set in line with market conditions and practice prevailing at the time of the issue of the Equity-Linked Financing Instruments, of a re-setting of the terms and conditions, or of the new shares.

 

Acquisition Rights shall be exercised by way of written notice to the company or in another form as determined by the board of directors.”

 

Artikel 3d – Kapitalband

 

Der Verwaltungsrat ist ermächtigt, jederzeit bis zum 31. Dezember 2030 das derzeitige Aktienkapital der Gesellschaft durch die Ausgabe von maximal 70’703’906 Namenaktien mit einem Nennwert von je CHF 100/11’325 um nominal maximal CHF 624’317 + 25/453 zu erhöhen, wobei die obere Grenze des Kapitalbands nominal CHF 1’872’951 + 73/453 und die untere Grenze nominal CHF 1’248’634 + 50/453 beträgt. Mehrfache Erhöhungen (auch in Teilbeträgen) im Rahmen des Kapitalbands, der Befristung und der nachfolgenden Bestimmungen sind zulässig.

 

Der Verwaltungsrat legt den Ausgabebetrag, die Art der Einlagen, den Zeitpunkt der Ausgabe, die Bedingungen der Bezugsrechtsausübung und den Beginn der Dividendenberechtigung fest. Dabei kann der Verwaltungsrat neue Aktien mittels Festübernahme durch eine Bank oder einen anderen Dritten und anschliessenden

 

 

Angebots an die bisherigen Aktionäre ausgeben. Der Verwaltungsrat ist ermächtigt, den Handel mit Bezugsrechten zu beschränken oder auszuschliessen. Nicht ausgeübte Bezugsrechte kann der Verwaltungsrat verfallen lassen oder diese bzw. die Aktien, für welche Bezugsrechte eingeräumt, aber nicht ausgeübt werden, zu Marktkonditionen platzieren oder anderweitig im Interesse der Gesellschaft verwenden.

 

Der Verwaltungsrat ist ermächtigt, die Bezugsrechte der Aktionäre zu entziehen oder zu beschränken und Bezugsrechte einzelnen Aktionären oder Dritten zuzuweisen:

 

(i)

sofern die Aktien für die Übernahme von Unternehmen, Unternehmensteilen oder Beteiligungen oder für die Finanzierung oder Refinanzierung solcher Transaktionen, die Umwandlung von Darlehen oder Wertschriften in Aktien, die Finanzierung von neuen Investitionsvorhaben der Gesellschaft, den Erwerb oder die Finanzierung von Produkten, geistigem Eigentum oder Lizenzen oder die Finanzierung von strategischen Initiativen verwendet werden;

 

(ii)

sofern die Aktien zum Zwecke der Erweiterung des Aktionärskreises im Zusammenhang mit der Kotierung der Aktien an einer Börse, um den Streubesitz zu erhöhen, oder zur Beteiligung von strategischen Partnern verwendet werden;

 

(iii)

im Fall nationaler oder internationaler (auch privater) Platzierung von Aktien zu Marktkonditionen; oder

 

(iv)

sofern die Aktien zum Zwecke einer raschen und flexiblen Beschaffung von Eigenkapital, welche ohne Beschränkung oder Ausschluss des Bezugsrechts nur schwer oder zu schlechteren Bedingungen möglich wäre.

 

Article 3d – Capital Band

 

The Board of Directors is authorised to increase the current share capital of the Company at any time until 31 December 2030 by a maximum nominal amount of CHF 624,317 + 25/453 by issuing a maximum of 70,703,906 registered shares with a par value of CHF 100/11,325 each (common shares), whereby the upper limit of the capital band is nominally CHF 1’872’951 + 73/453 and the lower limit is nominally CHF 1,248,634 + 50/453. Multiple increases (also in instalments) within the framework of the capital band, the time limit and the following provisions are permitted.

 

The Board of Directors shall determine the amount of share capital to be issued, the type of contribution, the date of issue, the conditions governing the exercise of subscription rights and the commencement of dividend entitlement. The Board of Directors may issue new shares which are underwritten by a bank or other third party and subsequently offered to existing shareholders. The Board of Directors is authorised to restrict or to prohibit trading in the subscription rights to the new shares. In the event of subscription rights not being exercised, the Board of Directors may, at its discretion, either allow such rights to expire worthless, or place them or the shares to which they entitle their holders either at market prices or in some other manner commensurate with the interests of the Company.

 

The Board of Directors is authorized to withdraw or limit the subscription rights of shareholders and to allocate subscription rights to individual shareholders or third parties:

 

(i)

of the new shares being used to acquire companies, parts thereof or participations, or for the financing or refinancing of such transactions, for the conversion of loans or securities into shares, for the financing of new investment projects undertaken, the acquisition or financing of products, intellectual property or licenses, or the financing of strategic initiatives undertaken by the Company;

 

(ii)

of the new shares being used either to extend the shareholder base [in conjunction with the listing of the shares on any stock exchange] to increase the free float or for investment by strategic partners;

 

(iii)

of the new shares being placed nationally or internationally (including by way of private placement) at market conditions;

 

(iv)

the new shares being issued for the for the purpose of raising equity capital in a swift and flexible manner, where such raising of capital would be difficult or would only be possible at less favorable conditions if the subscription rights to the new shares were not restricted or withdrawn.

 

 

Art. 15 Abs. 1:

 

Der Verwaltungsrat besteht aus bis zu sieben Mitgliedern.

 

Art. 15 para. 1:

 

The Board of Directors shall consist of up to seven members.”

 

NOTE: The English text is provided solely as a translation of the German original. In case of doubt, the German version shall prevail.

 

 

Exhibit 99.2

 

 

 

Press Release

 

 

VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC^®-TCE Program

 

ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to advance VERAXA’s lead BiTAC-TCE program toward IND/CTA-enabling activities

 

 

ZURICH, SWITZERLAND – July 02, 2026 – VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC^® T-cell engager (BiTAC-TCE) program. VERAXA has engaged ATUM, a global leader in bioengineering and cell line development, to apply the proprietary Leap-In Transposase^® technology to support stable clonal cell line generation. The collaboration marks a key step in progressing VERAXA’s most advanced T-cell engager candidate toward IND/CTA-enabling activities and supports future clinical development.

 

“Today’s news underscores our commitment to accelerate the development path of our growing BiTAC-TCE portfolio. Initiating cell line development with ATUM is an important next step for our lead BiTAC-TCE program following the encouraging preclinical data we presented at AACR,” said Christoph Erkel, Ph.D., Vice President Research & Development of VERAXA. “Working with a recognized cell line development partner like ATUM allows us to pair our differentiated molecular design with expertise and workflows built for exactly this kind of advanced multi-chain formats.”

 

Cell line development is an important milestone in translating a therapeutic candidate into a manufacturable product. The collaboration with ATUM is intended to support the generation of stable and high-producing clonal cell lines that will be used throughout CMC development, including early process, analytical, and formulation development, as well as the supply of material for nonclinical studies. ATUM’s Leap-In Transposase^® technology is designed to support efficient stable cell line generation and is particularly relevant for multi-chain antibody formats where balanced expression of multiple components is important, such as VERAXA’s BiTAC-TCEs. ATUM’s Leap-In Transposase^® technology has supported the generation of stable cell lines used in over 50 IND submissions, providing VERAXA with an established cell line development approach for advanced biologic formats.

 

A new generation of T-cell engagers

 

T-cell-engaging bispecific molecules redirect cytotoxic T-cells to eliminate cancer cells, typically by binding the CD3 receptor on T-cells while simultaneously engaging a target protein on the tumor. While effective in select indications, conventional TCEs remain limited by toxicity; because their tumor target is often also present on healthy tissue, on-target but off-tumor T-cell activation can drive serious side effects and narrow the therapeutic window. A large proportion of conventional bispecific TCEs fail in development for this reason.

 

 

 

VERAXA’s BiTAC-TCE approach is designed to address this challenge at its source. Rather than delivering a single, fully active molecule, the BiTAC strategy splits the T-cell engager into two complementary precursors. In their isolated form, each precursor retains its tumor-binding capability while the CD3-binding function remains inactivated. Only when both precursors bind their respective targets on the same cell is the CD3-binding domain reconstituted and activated. This “AND”-gated mechanism restricts T-cell activity to cells displaying both tumor markers, sparing healthy cells that carry only one.

 

A dual-target, conditional-activation design distinguishes BiTAC-TCEs from both traditional TCEs and from masked-TCE approaches that rely on a single antibody whose effector function is shielded until cleaved in the tumor microenvironment. By requiring the simultaneous engagement of two distinct antigens to assemble the active engager, BiTAC-TCEs are engineered for greater tumor selectivity, with the goal of enabling higher dosing and a meaningfully wider therapeutic window.

 

Initial data from VERAXA’s most advanced BiTAC-TCE program were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, in April. In those studies, VERAXA’s BiTAC-TCE candidate performed as intended in vitro and in vivo, attacking cancer cells displaying both target molecules while sparing cells expressing only one of the two targets. The data demonstrated a superior safety profile with matching efficacy compared with a more traditional TCE, pointing to the possibility of a meaningfully improved therapeutic index. The related posters are available on the VERAXA website at www.veraxa.com.

 

About VERAXA Biotech AG (NASDAQ: VRXA)

 

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

 

For regular updates about VERAXA Biotech, visit https://investors.veraxa.com/ or follow us on LinkedIn, X (formerly known as Twitter) and Bluesky.

 

BiTAC^® is a registered trademark of VERAXA Biotech GmbH.

 

About ATUM

 

ATUM is a fully integrated biotechnology contract research organization that provides services for gene design, protein engineering, and cell line development. By combining machine learning, synthetic biology, and proprietary expression technologies, ATUM helps partners worldwide transform digital sequences into clinical reality. ATUM is headquartered in Newark, Calif. and found online at www.atum.bio.

 

 

 

Forward-looking Statements

 

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that address activities, events, or developments that VERAXA Biotech AG (the “Company”) intends, expects, plans, projects, believes, or anticipates will or may occur in the future are forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements contained on this press release should be evaluated together with the many uncertainties that affect the Company’s business, particularly those identified in the risk factors section of the Company’s registration statement on Form F-4. These documents are available from the Securities and Exchange Commission, the Company website or from Company Investor Relations.

 

In addition, any information contained in this press release was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, the company will not update the information contained in this press release and investors should not rely upon the information as current or accurate after the presentation date. The press release may also contain certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the Company’s website at www.veraxa.com.

 

Contact

 

VERAXA Biotech AG - Corporate

Christoph Antz, Ph.D.

Chief Executive Officer, Co-Founder

investors@veraxa.com

 

For Media and Investors – U.S.

Brandon Weiner

ICR Healthcare

VERAXA@icrhealthcare.com

 

For Media and Investors – EU

Mario Brkulj

media@veraxa.com

 

 

Exhibit 99.3

 

 

 

Press Release

 

 

VERAXA Biotech Provides Business Update and Further Details on
Partnering Strategy and Development Timelines

 

Novel conditionally active T cell engagers sourced from proprietary BiTAC^® platform are at the basis of advanced partnering initiatives and development activities

 

 

ZURICH, SWITZERLAND – July 6, 2026 – VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided a company and pipeline update.

 

“In the first six months of 2026, we have made substantial progress in honing our pipeline and partnering strategy. We continue to record tangible interest in our novel BiTAC^® technology and its applications in building a range of BiTAC-T cell engagers and BiTAC-antibody-drug conjugates,” stated Dr. Christoph Antz, Ph.D., Chief Executive Officer of VERAXA Biotech. “BiTAC molecules are expected to dominate our pipeline development efforts in the years to come and mature to be the main value drivers of the company. Therefore, we intend to channel the lion’s share of our investments into our BiTAC portfolio and aim to monetize selected non-BiTAC pipeline assets early to finance its growth. It is our firm goal to have a first BiTAC-TCE candidate VXA-102 IND/CTA-ready by the beginning of 2028.”

 

The company’s pipeline currently consists of four BiTAC-based therapeutic programs aimed at treating various solid tumor indications. Mirroring the more advanced state of development of the BiTAC-TCE platform, all of these programs are T cell engagers. Complementing our BiTAC portfolio are currently two bispecific ADCs (bs ADCs) with more traditional molecular design. This includes the bsADC program pursued within a strategic partnership with OmniAb, Inc. The formally most advanced program in VERAXA’s portfolio, the Fc-enhanced FLT3-targeting monoclonal antibody VXA-901 for the treatment of acute myeloid leukemia (AML), and the company’s HER2-targeting ADC program are available for partnering.

 

“Interest in novel technologies and drug development programs in the T cell engager and ADC space continues to be at a record high in the pharmaceutical industry. To benefit from this positive partnering environment, it is crucial to have a clearly differentiated technology, which we have with our BiTAC platform,” added Heinz Schwer, Ph.D., MBA, Chief Business Officer of VERAXA. “The recent BIO International Partnering Conference turned out to be a well-timed opportunity for us to meet with potential new partners and also to intensify our ongoing discussions. The feedback received at this and other recent industry and scientific events gives as a great level of confidence that, with continued validation of our platform and products, we will be well positioned to secure initial partnerships.”

 

 

 

 

About VERAXA Biotech AG (NASDAQ: VRXA)

 

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including conditionally active T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of TCEs, ADCs, and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

 

For regular updates about VERAXA Biotech, visit www.veraxa.com or follow us on LinkedIn, X (formerly known as Twitter) and Bluesky.

 

BiTAC^® is a registered trademark of VERAXA Biotech GmbH.

 

Forward-looking Statements

 

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that address activities, events, or developments that VERAXA Biotech AG (the “Company”) intends, expects, plans, projects, believes, or anticipates will or may occur in the future are forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations, including with respect to the company’s anticipated pipeline development focus, its ability to monetize its pipeline assets, the timing for development of its pipeline candidates and the ability of the company to partner its pipeline assets. No forward-looking statement can be guaranteed. Forward-looking statements contained on this press release should be evaluated together with the many uncertainties that affect the Company’s business, particularly those identified in the risk factors section of the Company’s registration statement on Form F-4. These documents are available from the Securities and Exchange Commission, the Company website or from Company Investor Relations.

 

In addition, any information contained in this press release was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, the company will not update the information contained in this press release and investors should not rely upon the information as current or accurate after the presentation date.

 

 

 

 

Contact

 

VERAXA Biotech AG – Corporate
Christoph Antz, Ph.D.
Chief Executive Officer, Co-Founder
investors@veraxa.com

 

For Media and Investors – U.S.
Brandon Weiner
ICR Healthcare
VERAXA@icrhealthcare.com

 

For Media and Investors – EU
Mario Brkulj
media@veraxa.com